Cited by 967Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Open access

Peggs, Karl S., Quezada, Sergio A., Chambers, Cynthia A., Korman, Alan J., Allison, James P.·2009·Journal of Experimental Medicine

DOI 10.1084/jem.20082492PMC PMC2722174

Open this paper in CoChat — free account Open PDF

Abstract

Cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) is a critical negative regulator of immune responses. Uniquely among known inhibitory receptors, its genetic ablation results in a fulminating and fatal lymphoproliferative disorder. This central regulatory role led to the development of antibodies designed to block CTLA-4 activity in vivo, aiming to enhance immune responses against cancer. Despite their preclinical efficacy and promising clinical activity against late stage metastatic melanoma, the critical cellular targets for their activity remains unclear. In particular, debate has focused on whether the effector T cell (Teff) or regulatory T cell (T reg cell) compartment is the primary target of antibody-mediated blockade. We developed a mouse expressing human instead of mouse CTLA-4, allowing us to evaluate the independent contributions of CTLA-4 blockade of each T cell compartment during cancer immunotherapy in an in vivo model of mouse melanoma. The data show that although blockade on effector cells significantly improves tumor protection, unicompartmental blockade on regulatory cells completely fails to enhance antitumor responses. However, concomitant blockade of both compartments leads to a synergistic effect and maximal antitumor activity. We conclude that the combination of direct enhancement of Teff cell function and concomitant inhibition of T reg cell activity through blockade of CTLA-4 on both cell types is essential for mediating the full therapeutic effects of anti–CTLA-4 antibodies during cancer immunotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1084/jem.20082492

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citation
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation
Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206
Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses
Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,785
Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Self-citation
Modulation of tryptophan catabolism by regulatory T cells
Fallarino, F., Grohmann, U., Hwang, K. W., Orabona, C., Vacca, C., Bianchi, R., Belladonna, M. L., Fioretti, M. C., Alegre, M., & Puccetti, P. (2003) · Nature Immunology · doi:10.1038/ni1003 · Cited by 1,375
Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.
Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., & Nakayama, E. (1999) · PubMed · Cited by 1,062
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020
Self-citation

Flagged first, then by citations

Show all 34 references

1 of the 34 references couldn’t be matched to a known paper.

Sorted by citations

Items 701–800 of 967

Quelle place pour les associations de l’immunothérapie à la chimiothérapie ou de plusieurs immunothérapies ?
Douchet, G., & Aspeslagh, S. (2017) · Bulletin du Cancer · doi:10.1016/j.bulcan.2017.03.008 · Cited by 6
Cancer immunotherapy by targeting immune checkpoint receptors
Isakov, N. (2018) · World Journal of Immunology · doi:10.5411/wji.v8.i1.1 · Cited by 6
Monoclonal Antibodies for Cancer Immunotherapy
Zarnani, A., Jafari, D., Bozorgmehr, M., Shabani, M., Leila, B. Y., Ghaemimanesh, F., & Jeddi‐Tehrani, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-50287-4_15 · Cited by 6
Pyroptosis: a novel signature to predict prognosis and immunotherapy response in gliomas
He, G., Chen, Z., Zhuo, S., Tang, J., Hao, W., Yang, K., & Yang, C. (2022) · Human Cell · doi:10.1007/s13577-022-00791-5 · Cited by 6
Phenotypes and Functions of Human Dendritic Cell Subsets in the Tumor Microenvironment
Sakref, C., Bendriss‐Vermare, N., & Valladeau‐Guilemond, J. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-2938-3_2 · Cited by 6
Immune checkpoint inhibitors and SARS-CoV2 infection
Abdolmohammadi‐Vahid, S., Baradaran, B., Adcock, I. M., & Mortaz, E. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112419 · Cited by 6
Therapeutic strategy for cancer immunotherapy in head and neck cancer
Ishii, H., Tanaka, S., & Masuyama, K. (2015) · Advances in Cellular and Molecular Otolaryngology · doi:10.3402/acmo.v3.27690 · Cited by 6
Update on vaccine development for renal cell cancer
Storkus, W. J. (2010) · Research and Reports in Urology · doi:10.2147/oaju.s7242 · Cited by 6
Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances
Keenan, B. P., Jaffee, E. M., & Armstrong, T. D. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0011 · Cited by 6
Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment
Carreira, B., Acúrcio, R. C., Matos, A. I., Peres, C., Pozzi, S., Vaskovich‐Koubi, D., Kleiner, R., Bento, M., Satchi‐Fainaro, R., & Florindo, H. F. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000147 · Cited by 6
Current Understanding of Nonsurgical Interventions for Refractory Differentiated Thyroid Cancer: a Systematic Review
Jones, H., Green, V., England, J. A., & Greenman, J. (2021) · Future Science OA · doi:10.2144/fsoa-2021-0041 · Cited by 6
PD-1/L1 With or Without CTLA-4 Inhibitors Versus Chemotherapy in Advanced Non-Small Cell Lung Cancer
Guo, L., Liang, J., Dai, W., Li, J., Si, Y.-X., Ren, W., Lu, Y., & Chen, D. (2022) · Cancer Control · doi:10.1177/10732748221107590 · Cited by 6
Murine bone marrow chimeras developing autoimmunity after CTLA-4-blockade show an expansion of T regulatory cells with an activated cytokine profile
Somer, L. D., Fevery, S., Bullens, D. M. A., Rutgeerts, O., Lenaerts, C., Mathieu, C., Boon, L., Kasran, A., Waer, M., & Billiau, A. (2010) · Immunology Letters · doi:10.1016/j.imlet.2010.06.005 · Cited by 6
[High circulating levels of adrenomedullin and endothelin-1 in obesity associated with arterial hypertension].
Letizia, C., Celi, M., Cerci, S., Scuro, L., Delfini, E., Subioli, S., Caliumi, C., & D'Erasmo, E. (2001) · PubMed · Cited by 6
Intron retention as a novel source of cancer neoantigensPreprint
Smart, A., Margolis, C. A., Pimentel, H., He, M. X., Miao, D., Adeegbe, D. O., Fugmann, T., Wong, K., & Allen, E. M. V. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/309450 · Cited by 6
Regulatory T Cells in Colon Cancer: Implications for Pathogenesis, Prognosis and Emerging Therapeutic Strategies
Muhammad, F. A., Shareef, A., Jyothi, S. R., Kumar, S., Chauhan, A. S., Gautam, A., Джамшедовна, А. М., Sameer, H. N., Yaseen, A., Athab, Z. H., et al. (2025) · Immunological Investigations · doi:10.1080/08820139.2025.2529970 · Cited by 7
Quantification of Receptor Occupancy by Ligand—An Understudied Class of Potential Biomarkers
Veeramani, S., & Weiner, G. J. (2020) · Cancers · doi:10.3390/cancers12102956 · Cited by 5
Prokaryotic expression of woodchuck cytotoxic T lymphocyte antigen 4 (wCTLA-4) and preparation of polyclonal antibody to wCTLA-4
Yang, Y., Wang, B., Yang, D., Lu, M., & Xu, Y. Y. (2011) · Protein Expression and Purification · doi:10.1016/j.pep.2011.10.007 · Cited by 5
Prospects for the use of ipilimumab in treating advanced prostate cancer
Wei, X. X., Fong, L. H., & Small, E. J. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1136284 · Cited by 5
Response Challenges to Cancer Immunotherapies
Al-Janabi, I. I. (2022) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v2i.65 · Cited by 5
Current immune therapeutic strategies in advanced or metastatic non-small cell lung cancer
Xu, J., Liu, C., Wu, X., & Ma, J. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002536 · Cited by 6
Bioinformatics-based design of a fusion vaccine with CTLA-4 variable region to combat Brucella
Guo, W. H., Zhu, Y., Haimiti, G., Xie, X., Niu, C., Li, M., Shi, J., Yin, Z. W., Yu, M. K., Ding, J., et al. (2023) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x2023e12938 · Cited by 5
Melanoma Vaccines and Modulation of the Immune System in the Clinical Setting: Building from New Realities
Rowdo, F. P. M., Lacreu, M. L., & Mordoh, J. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00103 · Cited by 5
The prognostic significance of immune checkpoint receptor expression in patients with lymphoma: Association with disease status and clinical outcomes
Shokrgozar, N., Dehghani, M., Golmoghaddam, H., Moghadam, M., Rezaei, N., Moayed, V., & Arandi, N. (2022) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13730 · Cited by 5
Introduction on Cancer Immunology and Immunotherapy
Rezaei, N., Aalaei‐Andabili, S. H., & Kaufman, H. L. (2014) · Springer eBooks · doi:10.1007/978-3-662-44006-3_1 · Cited by 5
Innate and Adaptive Immune Responses to Cancer
Rausch, M. P., & Hastings, K. T. (2019) · Springer eBooks · doi:10.1007/978-3-030-15935-1_5 · Cited by 5
Correction: Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients
Fong, B., Jin, R., Wang, X., Safaee, M., Lisiero, D. N., Yang, I., Li, G., Liau, L. M., & Prins, R. M. (2012) · PLoS ONE · doi:10.1371/annotation/921cda8a-d169-49b8-9dfc-5ee32271b729 · Cited by 5
Mechanism of Action and Pharmacologic Features of Drugs Targeting PD ‐1/ PDL ‐1 and CTLA ‐4
Rodriguez, M., Bucktrout, R., Orlando, A., Serganova, I. S., & Zappasodi, R. (2024) · Wiley eBooks · doi:10.1002/9781119824572.ch11 · Cited by 5
The immune microenvironment in tumors: focus on canine and feline spontaneous neoplasms
Rizzi, M., D’Annunzio, G., Tugnoli, C., Sarli, G., & Muscatello, L. V. (2025) · Frontiers in Veterinary Science · doi:10.3389/fvets.2025.1674694 · Cited by 4
Evolving frontiers in bladder cancer immunotherapy: integrating BCG, immune checkpoints, viral vectors, nanotechnology, and CAR-based therapies
Spirito, A. D., Zuccolotto, G., Tosi, A., Balkhi, S., Rosato, A., Baci, D., & Mortara, L. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1719978 · Cited by 4
The Goat Cytotoxic T Lymphocyte-Associated Antigen-4 Gene: mRNA Expression and Association Analysis of Insertion/Deletion Variants with the Risk of Brucellosis
Wang, C., Liu, X., Ren, Z., Du, X., Li, N., Song, X., Wu, W., Qu, L., Zhu, H., & Hua, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252010948 · Cited by 4
Intratumoral T reg cell ablation elicits NK cell–mediated control of CD8 T cell–resistant tumors
Zhang, C., Chien, C., Jurgaitytė, E., Sakiyama, K., Bockman, A., Jo, Y., Lee, S., Silveria, S. L., Andrews, E., Mende, A., et al. (2026) · Science Immunology · doi:10.1126/sciimmunol.adx4411 · Cited by 4
Harnessing the Immune System to Fight Cancer: The Promise of Genetic Cancer Vaccines
Aurisicchio, L., & Ciliberto, G. (2011) · InTech eBooks · doi:10.5772/24410 · Cited by 4
Differential RNA expression of immune-related genes and tumor cell proximity from intratumoral M1 macrophages in acral lentiginous melanomas treated with PD-1 blockade
Kim, S., Kim, J. R., Lee, J. H., Moon, S.-H., Jo, S. I., Bae, D., Park, M., Lee, S., Kim, J.-O., Lee, C., et al. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2022.166516 · Cited by 4
Immunosuppressive mechanisms of oncofetal reprogramming in the tumor microenvironment: implications in immunotherapy response.
Currenti, J., Mishra, A., Wallace, M., George, J., & Sharma, A. (2023) · PubMed Central · doi:10.1042/bst20220157 · Cited by 5
Immunotherapy in liver transplantation for hepatocellular carcinoma: A comprehensive review
Akabane, M., Imaoka, Y., Kawashima, J., Schenk, A. D., & Pawlik, T. M. (2024) · Journal of Liver Transplantation · doi:10.1016/j.liver.2024.100256 · Cited by 4
Emerging Role for Novel Immunotherapy Agents in Metastatic Renal Cell Carcinoma: From Bench to Bedside
Weinstock, M., & McDermott, D. F. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e291 · Cited by 4
Immune Co-signaling to Treat Cancer
Callahan, M. K., Wolchok, J. D., Allison, J. P., & Sharma, P. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4732-0_8 · Cited by 4
Self-citation
Role of the Crosstalk Between CTLA-4 and NKG2D in the Development of Anti-CTLA-4 Treatment Strategies
Demaria, S., & Dustin, M. L. (2013) · Immunotherapy · doi:10.2217/imt.12.160 · Cited by 4
Immune checkpoint pathways: perspectives on myeloid malignancies
Rivera, G. A., Behbahan, I. S., & Greenberg, P. L. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1107554 · Cited by 4
Development of a flow cytometry assay which allows to evaluate the efficiency of immunomodulatory vaccines to enhance T cell-mediated antitumor response
Manrique-Rincón, A., de Carvalho, A. C., de Camargo, M. E. R., Franchini, K. G., & Bajgelman, M. C. (2018) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2018.07.029 · Cited by 4
The Role of Regulatory T Cells and Indoleamine-2,3-dioxygenase in Brain Tumor Immunosuppression
Dey, M., Chang, A. L., Miska, J. M., Qiao, J., & Lesniak, M. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802420-1.00003-x · Cited by 4
Immunotherapy of Hodgkin Lymphoma: Mobilizing the Patient's Immune Response
Ansell, S. M. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000331 · Cited by 4
Introduction on Cancer Immunology and Immunotherapy
Rezaei, N., Aalaei‐Andabili, S. H., Amini, N., Delavari, F., Keshavarz‐Fathi, M., & Kaufman, H. L. (2020) · Springer eBooks · doi:10.1007/978-3-030-30845-2_1 · Cited by 4
Stoking an anti-liver cancer immune response with cryoablation plus an intratumoral TLR9 agonist and dual checkpoint inhibitors
Yang, Y., Mandt, T., Mittelstein, D. R., Das, M., Wu, P., Ghani, M. A., Illindala, R., Steinmetz, N. F., Burgoyne, A., Berman, Z. T., et al. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04286-8 · Cited by 3
Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironment
Maltez, V. I., Arora, C., Gribbin, K. P., Caruso, B. P., Haerr, M. E., Sor, R., Lian, Q., Blise, K. E., Sivagnanam, S., Sears, R. C., et al. (2026) · Immunity · doi:10.1016/j.immuni.2026.03.011 · Cited by 3
Targeting Histone 3 Variants Epigenetic Landscape and Inhibitory Immune Checkpoints: An Option for Paediatric Brain Tumours Therapy
Meenakshi, S., Maharana, K. C., Nama, L., Vadla, U. K., Dhingra, S., Ravichandiran, V., Murti, K., & Kumar, N. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230809110444 · Cited by 3
The potential role of exercise in mitigating fertility toxicity associated with immune checkpoint inhibitors (ICIs) in cancer patients
Jamrasi, P., Tazi, M., Zulkifli, N. A. B., Bae, J. H., & Song, W. J. (2024) · The Journal of Physiological Sciences · doi:10.1186/s12576-024-00950-3 · Cited by 3
Update on immunotherapy‐mediated colitis: Clinical features, mechanisms, and management
Wang, D., Zhao, Y., Zeng, Y., Hu, L., & Xu, C. S. (2024) · Malignancy Spectrum · doi:10.1002/msp2.50 · Cited by 3
The Swinging Pendulum of Cancer Immunotherapy Personalization
Abraham, T. S., & Snook, A. E. (2017) · Personalized Medicine · doi:10.2217/pme-2016-0108 · Cited by 3
Targeting Immune Checkpoint
Espósito, A., & Curigliano, G. (2017) · Springer eBooks · doi:10.1007/978-3-319-48848-6_66 · Cited by 3
An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions
Zhang, J., Späth, S. S., Weissman, S. M., & Katz, S. G. (2019) · Methods in molecular biology · doi:10.1007/978-1-0716-0203-4_10 · Cited by 3
Immunotherapy and Antivascular Targeted Therapy in Patients’ Treatment with Concurrent Malignant Tumors after Organ Transplantation: Opportunity or Challenge
Shen, B., Guo, Z., Huang, P., Tan, M., Zhang, X., Lin, S., Song, C., Wang, J., & Huang, M. (2022) · Journal of Immunology Research · doi:10.1155/2022/6440419 · Cited by 3
A Novel Notch-Related Gene Signature for Prognosis and Immune Response Prediction in Ovarian Cancer
Pi, Y., Sun, F., Zhang, Z., Liu, X., & Lou, G. (2023) · Medicina · doi:10.3390/medicina59071277 · Cited by 3
Time for hepatocellular carcinoma immunotherapy: insights for successful clinical applications in this challenging tumor
Missale, G., & Cariani, E. (2018) · Hepatoma Research · doi:10.20517/2394-5079.2018.72 · Cited by 3
Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target
Carpenter, C. D., Alnahhas, I., Gonzalez, J., Giglio, P., & Puduvalli, V. K. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1621169 · Cited by 3
Prognostic and predictive role of the tumor immune landscape
Haanen, J. B. A. G., & Blank, C. U. (2020) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.20.03255-0 · Cited by 3
Immunotherapy for Prostate Cancer: An Evolving Landscape
Mao, W., & Drake, C. G. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_35 · Cited by 3
Success of immune checkpoint blockade therapies – mechanisms and implications for hepatology
Bengsch, B., & Thimme, R. (2019) · Zeitschrift für Gastroenterologie · doi:10.1055/a-0805-6936 · Cited by 4
Cancer Immunology
Pardoll, D. M. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00006-0 · Cited by 4
Bispecific antibodies: A promising entrant in cancer immunotherapy
Saini, S., & Kumar, Y. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821972-0.00014-9 · Cited by 3
Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma
Dai, X., Wang, S., Niu, C., Ji, B., & Liu, Y. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820947486 · Cited by 3
FcyRIIB Is a Novel Immune Checkpoint in the Tumor Microenvironment Limiting Activity of Treg-Targeting AntibodiesPreprint
Knorr, D. A., Leidner, R. S., Jensen, S. M., Meng, R., Jones, A., Ballesteros‐Merino, C., Bell, R. B., Baez, M., Sprott, D., Bifulco, C. B., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.19.522856 · Cited by 3
Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic EfficacyPreprint
Keshari, S., Shavkunov, A. S., Miao, Q., Saha, A., Williams, C. D., Highsmith, A. M., Pineda, J. E., Alspach, E., Hu, K. H., Pauken, K. E., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4755484 · Cited by 3
Developing an Effective Therapeutic HPV Vaccine to Eradicate Large Tumors by Genetically Fusing Xcl1 and Incorporating IL-9 as Molecular Adjuvants
Sun, Z., Wu, Z., & Su, X. (2025) · Vaccines · doi:10.3390/vaccines13010049 · Cited by 2
Next-generation cancer therapies: translating experimental advances into clinical practice
Kale, E., Guzes, E., Alatas, F., & Sharafi, P. (2025) · Postgraduate Medical Journal · doi:10.1093/postmj/qgaf242 · Cited by 3
Immune checkpoint inhibitors in bladder cancer: from mechanistic insights to emerging combination frontlines
Ajalli, M. M., Sansebli, Y., Ekrami, D., Alaeenejad, F., Abbasi, A., Eini, P., Hassanzadeh, F., & Bahrami, N. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02098-3 · Cited by 2
Embryonic-Like Stem Cells Derived from Postpartum Placenta Delivered After Spotaneous Labor Emerging as Universal Prophylactic Cancer Vaccine
Corocleanu, M. (2012) · Journal of Vaccines & Vaccination · doi:10.4172/2157-7560.1000163 · Cited by 1
Inhibitory immunologicznych punktów kontrolnych podziału komórki w leczeniu chorób nowotworowych
Mędra, A., Majchrzak, A., & Smolewski, P. (2016) · Acta Haematologica Polonica · doi:10.1016/j.achaem.2016.04.008 · Cited by 2
Cancer Immunotherapy with Vaccines and Checkpoint Blockade
Pardoll, D. M. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00052-4 · Cited by 2
Immune Checkpoints and Inhibitors
Aksu, Ö. B., & Şengül, Ş. (2020) · Journal of Ankara University Faculty of Medicine · doi:10.4274/atfm.galenos.2019.24382 · Cited by 2
MALT1 inhibition suppresses antigen-specific T cell responses
Kerzeli, I. K., Nasi, A., Fletcher, E. A. K., Chourlia, A., Kallin, A., Finnberg, N. K., Ersmark, K., Lampinen, M., Albertella, M. R., Oberg, F. G., et al. (2024) · Cellular Immunology · doi:10.1016/j.cellimm.2024.104814 · Cited by 2
Perioperative Immune Checkpoint Inhibitors for the Treatment of Locally Advanced Gastric and Gastroesophageal Junction Cancer: Current Status and Future Prospects
Cui, S., Zhao, K., Wang, N., Meng, Y. G., Zhao, C., Liu, H., Wen, X., & Kong, F. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01353-1 · Cited by 2
Immunomodulatory Methods
Kassab, C., Kerrigan, B. C. P., Caruso, H. G., Al-Enazy, S., & Heimberger, A. B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813997-4.00015-3 · Cited by 2
Rationale, Visionen und Grenzen der Immunonkologie: Checkpoint-Inhibition als neue Therapiesäule der Tumortherapie
Hauschild, A., & Mohr, P. (2015) · Oncology Research and Treatment · doi:10.1159/000381298 · Cited by 2
Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab
Graziani, G., Tentori, L., & Navarra, P. (2013) · Springer eBooks · doi:10.1007/978-3-7091-1300-4_10 · Cited by 2
The use of baseline biomarkers to predict outcome in melanoma patients treated with pembrolizumab
Puri, S., & Markowitz, J. (2017) · Annals of Research Hospitals · doi:10.21037/arh.2017.04.24 · Cited by 2
Immune Response in Melanoma: A Basis to Understand the Role of Immunotherapy with Immune Checkpoint Inhibitors
Pires, E. M., & Moura, C. (2018) · Journal of the Portuguese Society of Dermatology and Venereology · doi:10.29021/spdv.76.1.868 · Cited by 2
Immune Checkpoint Inhibitors - New Insights and Recent Progress
Raza, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100958 · Cited by 2
Overcoming Cancer Tolerance with Immune Checkpoint Blockade
Clifton, G. T., Mittendorf, E. A., & Peoples, G. E. (2014) · Springer eBooks · doi:10.1007/978-3-662-44946-2_6 · Cited by 2
Innate and Adaptive Immune Responses to Cancer
Hastings, K. T., & Rausch, M. P. (2013) · Springer eBooks · doi:10.1007/978-3-642-38983-2_4 · Cited by 3
Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle
Marzolini, M. A. V., Quezada, S. A., & Peggs, K. S. (2015) · EMJ Oncology · doi:10.33590/emjoncol/10314057 · Cited by 2
Self-citation
Development of a Model to Study the Abscopal Effect: Combining Image-guided Radiation Therapy and Immunotherapy in Cancer Treatment
Moretti, A. (2011) · TSpace (University of Toronto) · Cited by 2
Attenuation of Immune Suppression to Complement Glioma Immunotherapy
Field, C. S. (2016) · doi:10.26686/wgtn.17013761.v1 · Cited by 2
Inflammation and Head and Neck Squamous Cell Carcinoma
Clavijo, P. E., Allen, C. T., Schmitt, N. C., & Waes, C. V. (2018) · Current cancer research · doi:10.1007/978-3-319-78762-6_13 · Cited by 1
Tumor microenvironment immunotherapy: Transforming cancer treatment and immune checkpoint inhibitors - Future directions and challenges
Kumaravel, J. J., Anbalagan, G., Dilipan, E., Selvamani, M., & Balachandran, S. (2024) · Oral Oncology Reports · doi:10.1016/j.oor.2024.100391 · Cited by 1
Blocking Co-inhibitory Receptors: A Promising Cancer Immunotherapy strategy
Acharya, N. (2024) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-97-5508-0_2 · Cited by 1
A signal-seeking phase 2 study of tremelimumab in advanced cancers with high tumour mutational burden
Thavaneswaran, S., Lin, F. P. Y., Espinoza, D., Grady, J. P., Kok, P., Chinchen, S., Pavlakis, N., Andelkovic, V., Charakidis, M., Craft, P., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01156-5 · Cited by 1
T cell–intrinsic VISTA expression promotes resistance to CTLA-4 blockade by restricting CD8+ T cell responses
Gilmour, C., Delaney, E., Parthasarathy, P. B., Roy, D., Ta, H. M., Zakeri, A., Grandez, P. E., Patnaik, S., Zhang, K., Juric, I., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci195668 · Cited by 3
A meta-analysis of single agent and dual immune checkpoint inhibitors in metastatic triple negative breast cancer
Zavras, P. D., Lara-Martinez, H. R., Nie, Q., Li, M., He, Z., Kattoula, J. Y., Strossman, N., Connolly, R. M., Barroso‐Sousa, R., Chan, I. S., et al. (2026) · npj Breast Cancer · doi:10.1038/s41523-026-01042-8 · Cited by 1
From tumor microenvironment orchestrators to actionable targets: a systematic review of TAM-targeted therapies in triple-negative breast cancer
Pei, Y., Zhang, J., Li, C., Wang, Y., Yu, Q., & Chen, W. (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-026-02987-3 · Cited by 1
Neue Perspektiven in der immunologischen Krebstherapie
Rothschild, S. I., & Zippelius, A. (2012) · Therapeutische Umschau · doi:10.1024/0040-5930/a000330 · Cited by 1
Cytotoxic T Lymphocyte Antigen-4 Blockade Enhances Antitumor Immunity by Stimulating Melanoma-Specific
Motility, T.-C., Pentcheva‐Hoang, T., Simpson, T. R., Montalvo-Ortiz, W., & Allison, J. P. (2014) · Cited by 1
Self-citation
Regulatory T Cells and Cancer
Turk, M. J. (2014) · Springer eBooks · doi:10.1007/978-1-4899-8056-4_1 · Cited by 1
Cancer Immunotherapy: Overview in Brief
Beckhove, P. (2013) · Springer eBooks · doi:10.1007/978-94-007-6217-6_23 · Cited by 1
Nicht-kleinzelliges Lungenkarzinom: Neues aus der Immuntherapie
Reinmuth, N., Heigener, D. F., & Reck, M. (2015) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0041-100763 · Cited by 1
A personalized Approach for Targeting the Melanoma: Inhibition of Oncogenic Signaling in Combination with Small Molecules
Yin, N. B., & Muhammad, A. M. (2016) · General Medicine Open Access · doi:10.4172/2327-5146.1000238 · Cited by 1
Current Therapies and Future Directions in Treatment of Glioblastoma
Wang, J., Mugge, L. A., Giglio, P., & Puduvalli, V. K. (2017) · Current cancer research · doi:10.1007/978-3-319-56820-1_3 · Cited by 1
Dendritic Cell-Based Cancer Therapies: Current Status and Future Directions
Miah, S. M. S., Erick, T. K., & Emerich, D. F. (2017) · Molecular and translational medicine · doi:10.1007/978-3-319-57153-9_6 · Cited by 1
WITHDRAWN: Nouvelles stratégies innovantes en immunothérapie
Ghiringhelli, F. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.03.004 · Cited by 1

Authors: Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
University of Massachusetts Chan Medical School (US)
Medarex, Inc., Milpitas, CA 95035 3
Corresponding author: Allison, James P.
ORCID: Peggs, Karl S.
Quezada, Sergio A.
Korman, Alan J.
Allison, James P.
Venue: Journal of Experimental Medicine
Publisher: Rockefeller University Press
Published: 2009-07-06
Volume: 206
Issue: 8
Pages: 1717-1725
ISSN: 0022-1007 (ISSN-L)
1540-9538
DOI: 10.1084/jem.20082492
PMC: PMC2722174
OpenAlex: W2013043293
Cited by: 967
References: 34
Citations by year: 2026: 17 · 2025: 46 · 2024: 57 · 2023: 56 · 2022: 51 · 2021: 54 · 2020: 59 · 2019: 64 · 2018: 78 · 2017: 82 · 2016: 78 · 2015: 81 · 2014: 56 · 2013: 60 · 2012: 39
FWCI: 20.80
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: The Journal of Experimental Medicine (publishedVersion)
PubMed Central (publishedVersion, cc-by-nc-sa)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Funders: Howard Hughes Medical Institute
Cancer Research Institute
Bristol-Myers Squibb
Memorial Sloan-Kettering Cancer Center
University College London
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: CTLA-4, anti-CTLA-4 antibody, regulatory T cells, effector T cells, cancer immunotherapy, melanoma, immune checkpoint blockade, humanized mice, antitumor immunity, T cell tolerance
MeSH terms: Animals, Antibodies, Neoplasm, Humans, Immunosuppression Therapy, Immunotherapy, Melanoma, Experimental, Mice, Inbred C57BL, Mice, Transgenic, Recombinant Proteins, Antigens, CD, T-Lymphocyte Subsets, Mice, Knockout, Cell Line, Tumor, T-Lymphocytes, Regulatory, Mice, CTLA-4 Antigen, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks